Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Cover Layout Presentation name
Twitter \ Biogen on Twitter: "#DYK progressive supranuclear palsy (#PSP) wasn't discovered until 1963 due to its resemblance to Parkinson's disease? #PSPAwarenessMonth https://t.co/59rxSezyHe"
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's | Fierce Biotech
Biogen - Pioneers In Neuroscience
Medscape - After disappointing trial results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies. http://ms.spr.ly/6185Tn3JH | Facebook
Research | Pipeline
Biogen 2019 Outlook (NASDAQ:BIIB) | Seeking Alpha
Biogen's Tau Antibody Fails In PSP, But Alzheimer's Studies Continue :: Scrip
Biogen May Cut Jobs, Shutter Facilities to Streamline Ops and Free Up $400 Million for R&D | BioSpace
Biogen Ends Trial of Its Drug for PSP - CurePSP
Phil's Journal: My Good Friend Is the First to Receive Biogen's Alzheimer's Drug in New Trial - Being Patient
FAQ on FDA Approval of Aducanumab - CurePSP
Progressive Supranuclear Palsy Treatment Market Estimated to Reach A Valuation Of US$ 20.68 Million By 2027 – with AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc.,
PSP — Coleen Heaver
Gosuranemab: another Alzheimer's candidate to bite the dust
Overview of Tau immunotherapies in clinical trial. Indicated are... | Download Scientific Diagram
Biogen's Tau Antibody for Progressive Supranuclear Palsy Fails Trial | BioSpace
Biogen on Twitter: "Our #MultipleSclerosis (#MS) and progressive supranuclear palsy (#PSP) research will be highlighted in the poster sessions today at #AANAM https://t.co/4HA0yQOW8X" / Twitter
Cure PSP - Can Progressive Supranuclear Palsy (PSP) be treated at all? The PASSPORT trial is investigating whether a new investigational study drug may slow the progression of PSP. Biogen plan to
Anti-Tau Drugs for PSP Move into Phase II - CurePSP
Biogen deals the tau pipeline another blow | Evaluate
Biogen on Twitter: "#DYK…Progressive supranuclear palsy (#PSP) is a neurodegenerative disorder that affects the brain cells controlling balance, walking, coordination, eye movement, speech, swallowing and thinking. #AANAM https://t.co/uYb551MjJi" / Twitter
Biogen abandons tau antibody for Alzheimer's after phase 2 miss -
Biogen Discontinues Gosuranemab Trial in Progressive Supranuclear Palsy
Biogen on Twitter: "Chris Henderson, VP, Neuromuscular and Movement Disorders Research Unit, highlights the importance of an early Progressive Supranuclear Palsy (PSP) diagnosis #PSPAwareness https://t.co/xDnZaZYYhT" / Twitter
Biogen Acquires Alzheimer's and Parkinson's Asset from Pfizer in $710 Million Deal | BioSpace
Research - Tau Consortium
